Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct;39(10):e879-e881.
doi: 10.1111/jdv.20616. Epub 2025 Mar 7.

Efficacy and safety profile of anifrolumab in skin lesions of systemic lupus erythematosus

Affiliations

Efficacy and safety profile of anifrolumab in skin lesions of systemic lupus erythematosus

Yousra Kanbar et al. J Eur Acad Dermatol Venereol. 2025 Oct.
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211–221.
    1. Amoura Z, Bader‐Meunier B, Antignac M, Bardin N, Belizna C, Belot A, et al. French protocol for the diagnosis and management of systemic lupus erythematosus. Rev Med Interne. 2024;45(9):559–599.
    1. The CLASI (cutaneous LE disease area and severity index): an outcome instrument for cutaneous lupus erythematosus. J Am Acad Dermatol. 2005;52(3):AB6.
    1. Niebel D, De Vos L, Fetter T, Brägelmann C, Wenzel J. Cutaneous lupus erythematosus: an update on pathogenesis and future therapeutic directions. Am J Clin Dermatol. 2023;24(4):521–540.
    1. Grolleau C, Poisot T, Hadjadj J, Jachiet M, Mahevas T, Le Buanec H, et al. Transcriptomic analysis of one patient with lupus skin lesions treated with anifrolumab. J Eur Acad Dermatol Venereol. 2025;39:e306–e309. https://doi.org/10.1111/jdv.20283

LinkOut - more resources